- On **October 17, 2025**, Entero Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement offering of up to **$5,000,000** in gross proceeds, consisting of Promissory Notes and common stock purchase warrants.  **[1604191_0001104659-25-101519_tm2529176d1_ex10-1.htm:0]** **[1604191_0001104659-25-101519_tm2529176d1_8k.htm:1]** 
- An initial closing occurred on **October 17, 2025**, where the company sold a Promissory Note with a principal amount of **$500,000** and a Warrant to purchase up to **200,000 shares** of common stock for **$500,000**.  **[1604191_0001104659-25-101519_tm2529176d1_8k.htm:1]** 
- The Promissory Note has a maturity date of **one year and one day** from its issuance, is not convertible, and does not bear interest.  **[1604191_0001104659-25-101519_tm2529176d1_ex10-2.htm:0]** **[1604191_0001104659-25-101519_tm2529176d1_8k.htm:1]** 
- The Warrants are exercisable upon stockholder approval, have an exercise price of **$2.50 per share**, and expire five years from the stockholder approval date, with a maximum of **1,520,000 Warrant Shares** potentially issuable.  **[1604191_0001104659-25-101519_tm2529176d1_8k.htm:1]** 
- The net proceeds from the offering are intended for **general corporate purposes**, including working capital and potential acquisitions.  **[1604191_0001104659-25-101519_tm2529176d1_8k.htm:1]** **[1604191_0001104659-25-101519_tm2529176d1_ex10-1.htm:34]**

Entero Therapeutics, Inc. Enters into Private Placement Agreement

- Entero Therapeutics, Inc. (ENTO) **acquired 100% of GRID AI Corp** on **October 1, 2025**, a grid-edge, AI-driven software and device platform, positioning ENTO in the high-growth AI energy-infrastructure market.  **[1604191_0001104659-25-097138_tm2528018d1_ex99-1.htm:0]** 
- Following the acquisition, and subject to shareholder approval, former GRID AI shareholders will own approximately **82.5% of the fully diluted ENTO common stock**, while existing ENTO shareholders will retain approximately **17.5%**.  **[1604191_0001104659-25-097138_tm2528018d1_ex99-1.htm:1]** **[1604191_0001104659-25-097138_tm2528018d1_8k.htm:2]** 
- The transaction involved an exchange of **424,348 shares of ENTO common stock** and **38,801,546 shares of Series H Non-Voting Convertible Preferred Stock**.  **[1604191_0001104659-25-097138_tm2528018d1_8k.htm:2]** 
- ENTO believes the Share Exchange has helped it regain compliance with Nasdaq's minimum stockholders' equity requirement of **at least $2.5 million**.  **[1604191_0001104659-25-097138_tm2528018d1_8k.htm:9]**

Entero Therapeutics Acquires GRID AI

- Entero Therapeutics, Inc. (ENTO) appointed **Jason D. Sawyer** as its **non-employee interim Chief Executive Officer** through a consulting agreement with Access Alternative Group S.A..  **[1604191_0001104659-25-089562_tm2525441d2_ex10-1.htm:0]** **[1604191_0001104659-25-089562_tm2525441d2_8k.htm:2]** 
- The consulting agreement was dated September 8, 2025, and became **effective on September 4, 2025**.  **[1604191_0001104659-25-089562_tm2525441d2_ex10-1.htm:0]** **[1604191_0001104659-25-089562_tm2525441d2_8k.htm:2]** 
- Mr. Sawyer will receive **$12,500 per month** for his services, with the engagement renewable on a month-to-month basis.  **[1604191_0001104659-25-089562_tm2525441d2_8k.htm:2]** **[1604191_0001104659-25-089562_tm2525441d2_ex10-1.htm:4]** 
- The Company will **defend and indemnify** Mr. Sawyer in his capacity as CEO to the fullest extent permitted by Delaware General Corporation Law.  **[1604191_0001104659-25-089562_tm2525441d2_8k.htm:2]** **[1604191_0001104659-25-089562_tm2525441d2_ex10-1.htm:2]**

Entero Therapeutics (ENTO)